Determining molecular and genetic markers for severe EBV-mononucleosis
- Authors: Filatova E.N.1, Sakharnov N.A.1, Utkin O.V.1, Kulova E.A.2
-
Affiliations:
- Blokhina Nizhny Novgorod Scientific Research Institute ofEpidemiology and Microbiology
- Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation
- Issue: Vol 10, No 4 (2020)
- Pages: 707-716
- Section: ORIGINAL ARTICLES
- URL: https://journal-vniispk.ru/2220-7619/article/view/118859
- DOI: https://doi.org/10.15789/2220-7619-DMA-1271
- ID: 118859
Cite item
Full Text
Abstract
Epstein—Barr virus (EBV) is one of the etiological agents causing infectious mononucleosis. A severe form of the disease can result in developing serious complications, which risk might also depend on the state of patient’s immune system. To date, no specific tests for assessing a risk of developing severe disease form are available. Our study was aimed at identifying molecular genetic markers of severe EBV-infectious mononucleosis (EBV-IM) in immunocompetent peripheral blood cells. Expression of 483 genes and gene transcripts regulating apoptosis, proliferation and differentiation of immunocompetent cells was measured in the peripheral blood leukocytes from patients with severe and moderate EBV-IM as well as apparently healthy donors. A DNA-microarray designed by us and subsequent data processing were carried out by using custom-made “MiDA” software. To identify markers of a severe form of the pathology, expression of each gene and transcript was compared in EBV-IM patients and apparently healthy donors. For each gene and transcript, the level of expression fold change and significance for binary classification were determined. Genes and transcripts, characterized by the maximum values of two determined parameters while comparing patients with severe infection and healthy donors, as well as patients with severe and moderate EBV-IM forms, were selected as markers of severe EBV-IM. Genes and transcripts with differed expression in patients with moderate EBV-IM and healthy donors, were excluded from the list of markers. In addition, sex- and age-linked markers with differed expression were excluded as well. The markers for severe EBV-IM consisted of apoptosis regulators (BCL2L11, BIRC3 genes and XIAP.NM_001167 transcript) and splicing factors (CELF6 gene and SF1.NM_201995 transcript). Compared with donors and patients with a moderate form of the disease, a decreased expression of BCL2L11, BIRC3 genes, transcripts SF1.NM_201995 and XIAP.NM_001167, as well as increased expression of the CELF6 gene were detected in the blood of patients with severe EBV-IM. The functional role of identified molecular markers suggests that severe EBV-IM is characterized by suppressed mitochondrial and activated TRAF-dependent apoptosis pathways in immunocompetent cells. The expression pattern for select markers is specific for severe EBV-MI, not associated with patient sex and age. Thus, study data may be used to develop specific tools for assessing a risk of developing complications of EBV mononucleosis.
About the authors
E. N. Filatova
Blokhina Nizhny Novgorod Scientific Research Institute ofEpidemiology and Microbiology
Author for correspondence.
Email: filatova@nniiem.ru
ORCID iD: 0000-0002-6683-7191
Elena N. Filatova - PhD (Biology), Leading Researcher, Laboratory of Molecular Biology and Biotechnology.
603950, Nizhny Novgorod, Malaya Yamskaya str., 71, Phone: +7 (831) 469-79-46 (office). Fax: +7 (831) 469-79-20
Russian FederationN. A. Sakharnov
Blokhina Nizhny Novgorod Scientific Research Institute ofEpidemiology and Microbiology
Email: saharnov@nniiem.ru
ORCID iD: 0000-0003-3965-2033
Researcher, Laboratory of Molecular Biology and Biotechnology.
Nizhny Novgorod Russian FederationO. V. Utkin
Blokhina Nizhny Novgorod Scientific Research Institute ofEpidemiology and Microbiology
Email: utkino2004@mail.ru
ORCID iD: 0000-0002-0941-9890
PhD (Biology), Head of the Laboratory of Molecular Biology and Biotechnology.
Nizhny Novgorod Russian FederationE. A. Kulova
Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation
Email: dr_kulova@mail.ru
PhD (Medicine), Associate Professor, Infectious Diseases Department.
Nizhny Novgorod Russian FederationReferences
- Солнцев Л.А., Старикова В.Д., Сахарнов Н.А., Князев Д.И., Уткин О.В. Стратегия подбора зондов для изучения совокупности мРНК участников рецептор-опосредованного сигналинга апоптоза // Молекулярная биология. 2015. Т. 49, № 3. С. 457-465. doi: 10.7868/S0026898415030167(In Russ.)
- Филатова Е.Н., Уткин О.В. Роль некодирующих изоформ мРНК белок-кодирующих генов в регуляции генной экспрессии // Генетика. 2018. Т. 54, № 8. С. 879-887. doi: 10.1134/S0016675818080052 (In Russ)
- Arning S., Gruter P., Bilbe G., Kramer A. Mammalian splicing factor SF1 is encoded by variant cDNAs and binds to RNA. RNA, 1996, vol. 2, no. 8, pp. 794-810.
- Asslaber D., Watch N., Leisch M., Qi Y., Maeding N., Hufnagl C., Jansko B., Zaborsky N., Villunger A., Hartmann T.N., Greil R., Egle A. BIRC3 expression predicts CLL progression and defines treatment sensitivity via enhanced NF-kB nuclear translocation. Clin. Cancer Res., 2018, vol. 25, no. 6, pp. 1901-1912. doi: 10.1158/1078-0432.CCR.-18-1548
- Caslini C., Spinelli O., Cazzaniga G., Golay J., De Gioia L., Pedretti A., Breviario F., Amaru R., Barbui T., Biondi A., Introna M., Rambaldi A. Identification of two novel isoforms of the ZNF162 gene: a growing family of signal transduction and activator of RNA proteins. Genomics, 1997, vol. 42, no. 2, pp. 268-277. doi: 10.1006/geno.1997.4705
- Corioni M., Antih N., Tanackovic G., Zavolan M., Kramer A. Analysis of in situ pre-mRNA targets of human splicing factor SF1 reveals a function in alternative splicing. Nucleic Acids Res., 2011, vol. 39, no. 5, pp. 1868-1879. doi: 10.1093/nar/gkq1042
- Dunmire S.K., Odumade O.A., Porter J.L., Reyes-Genere J., Schmeling D.O., Bilgic H., Fan D., Baechler E.C., Balfour H.H. Jr., Hogquist K.A. Primary EBV infection induces an expression profile distinct from other viruses but similar to hemophagocytic syndromes. PLoS One, 2014, vol. 9, no. 1: e85422c. doi: 10.1371/journal.pone.0085422
- Fitzsimmons L., Boyce A.J., Wei W., Chang C., Croom-Carter D., Tierney R.J., Herold M.J., Bell A.I., Strasser A., Kelly G.L., Rowe M. Coordinated repression of BIM and PUMA by Epstein-Barr virus latent genes maintains the survival of Burkitt lymphoma cells. Cell Death Differ., 2018, vol. 25, no. 2, pp. 241-254. doi: 10.1038/cdd.2017.150
- Fu Q., He C., Mao Z. Epstein-Barr virus interactions with the Bcl-2 protein family and apoptosis in human tumor cells. J. Zhejiang Univ. Sci. B, 2013, vol. 14, no. 1, pp. 8-24. doi: 10.1631/jzus.B1200189
- Houldcroft C.J., Kellam P. Host genetics of Epstein-Barr virus infection, latency and disease. Rev. Med. Virol., 2015, vol. 25, no. 2, pp. 71-84. doi: 10.1002/rmv.1816
- Ladd A.N., Nguyen H.N., Malhorta K., Cooper A. CELF6, a member of the CELF family of RNA-binding proteins, regulates muscle-specific splicing enhancer-dependent alternative splicing. J. Biol. Chem., 2004, vol. 279, no. 17, pp. 17756-17764. doi: 10.1074/jbc.M310687200
- Lopez-Granados E., Stacey M., Kienzler A.-K., Sierro S., Willberg C.B., Fox C.P., Rigaud S., Long H.M., Hislop A.D., Rickinson A.B., Patel S., Latour S., Klenerman P., Chapel H. A mutation in X-linked inhibitor of apoptosis (G466X) leads to memory inflation of Epstein-Barr virus-specific T cells. Clin. Exp. Immunol., 2014, vol. 178, no. 3, pp. 470- 482. doi: 10.1111/cei.12427
- McAulay K.A., Higgins C.D., Macsween K.F., Lake A., Jarrett R.F., Robertson F.L., Williams H., Crawford D.H. HLA class I polymorphisms are associated with development of infectious mononucleosis upon primary EBV infection. J. Clin. Invest., 2007, vol. 117, no. 10, pp. 3042-3048. doi: 10.1172/JCI32377
- Pender M.P. CD8+ T-cell deficiency, Epstein-Barr virus infection, vitamin D deficiency, and steps to autoimmunity: a unifying hypothesis. Autoimmune Dis., 2012, vol. 2012:189096. doi: 10.1155/2012/189096
- Price A.M., Dai J., Bazot Q., Patel L., Nikitin P.A., Djavadian R., Winter P.S., Salinas C.A., Barry A.P., Wood K.C., Johann-sen E.C., Letai A., Allday M.J., Luftig M.A. Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection. eLife, 2017, vol. 6: e22509. doi: 10.7554/eLife.22509
- Price A.M., Luftig M.A. Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation. Adv. Virus Res., 2014, vol. 88,pp. 279-313. doi: 10.1016/B978-0-12-800098-4.00006-4
- Price A.M., Tourigny J.P., Forte E., Salinas R.E., Dave S.S., Luftig M.A. Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-kB activation. J. Virol,, 2012, vol. 86, no. 20,pp. 11096-11106. doi: 10.1128/JVI.01069-12
- Rigaud S., Fondaneche M.-C., Lambert N., Pasquier B., Ateo V., Soulas P., Galicier L., Le Deist F., Rieux-Laucat F., Revy P., Fischer A., de Saint Basile G., Latour S. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature, 2006, vol. 444, no. 7115, pp. 110-114. doi: 10.1038/nature05257
- Skinner C.M., Ivanov N.S., Barr S.A., Chen Y., Skalsky R.L. An Epstein-Barr virus microRNA blocks interleukin-1 (IL-1) signaling by targeting IL-1 receptor 1. J. Virol., 2017, vol. 91, no. 21: e00530-17. doi: 10.1128/JVI.00530-17
- Wood C.D., Veenstra H., Khasnis S., Gunnel A., Webb H.M., Shannon-Lowe C., Andrews S., Osborne C.S., West M.J. MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs. eLife, 2016, vol. 5: e18270. doi: 10.7554/eLife.18270
- Worth A.J.J., Houldcroft C.J., Booth C. Severe Epstein-Barr virus infection in primary immunodeficiency and the normal host. Br. J. Haematol., 2016, vol. 175, no. 4, pp. 559-576. doi: 10.1111/bjh.14339
Supplementary files
